ClearPoint Neuro to Announce Fourth Quarter and Full Year 2023 Results March 12, 2024
March 01 2024 - 4:05PM
ClearPoint Neuro, Inc. (NASDAQ: CLPT) (the “Company”), a global
device, cell, and gene therapy-enabling company offering precise
navigation to the brain and spine, today announced that it will
release financial results for its 2023 fourth quarter and full year
on Tuesday, March 12th, after the market close.
Investors and analysts are invited to listen to
the live broadcast review of the Company’s 2023 fourth quarter and
full year results on Tuesday, March 12th, at 4:30 p.m. Eastern time
(1:30 p.m. Pacific time) which may be accessed online here.
Investors and analysts who would like to participate in the
conference call via telephone may do so at (877) 407-9034, or at
(201) 493-6737 if calling from outside the U.S. or Canada.
For those who cannot access the live broadcast,
a replay will be available shortly after the completion of the call
until April 12, 2024, by calling (877) 660-6853 or (201) 612-7415
if calling from outside the U.S. or Canada, and then entering
conference I.D. number 413671. An online archive of the broadcast
will be available on the Company’s Investor website at
https://ir.clearpointneuro.com
About ClearPoint Neuro
ClearPoint Neuro is a device, cell, and gene
therapy-enabling company offering precise navigation to the brain
and spine. The Company uniquely provides both established clinical
products as well as preclinical development services for controlled
drug and device delivery. The Company’s flagship product, the
ClearPoint Neuro Navigation System, has FDA clearance and is
CE-marked. ClearPoint Neuro is engaged with healthcare and research
centers in North America, Europe, Asia, and South America. The
Company is also partnered with the most innovative
pharmaceutical/biotech companies, academic centers, and contract
research organizations, providing solutions for direct CNS delivery
of therapeutics in pre-clinical studies and clinical trials
worldwide. To date, thousands of procedures have been performed and
supported by the Company’s field-based clinical specialist team,
which offers support and services to our customers and partners
worldwide. For more information, please visit
www.clearpointneuro.com.
Forward-Looking Statements
Statements in this press release and in the
teleconference referenced above concerning the Company’s plans,
growth and strategies may include forward-looking statements within
the context of the federal securities laws. Statements
regarding the Company's future events, developments and future
performance, the size of total addressable markets or the market
opportunity for the Company’s products and services, as well as
management's expectations, beliefs, plans, estimates or projections
relating to the future, are forward-looking statements within the
meaning of these laws. These forward-looking statements are based
on management’s current expectations and are subject to the risks
inherent in the business, which may cause the Company's actual
results to differ materially from those expressed in or implied by
forward-looking statements. Particular uncertainties and risks
include those relating to: global and political instability, supply
chain disruptions, labor shortages, and macroeconomic and
inflationary conditions; future revenue from sales of the Company’s
products and services; the Company’s ability to market,
commercialize and achieve broader market acceptance for new
products and services offered by the Company; the ability of our
biologics and drug delivery partners to achieve commercial success,
including their use of the Company’s products and services in their
delivery of therapies; the Company’s expectations, projections and
estimates regarding expenses, future revenue, capital requirements,
and the availability of and the need for additional financing; the
Company’s ability to obtain additional funding to support its
research and development programs; the ability of the Company to
manage the growth of its business; the Company’s ability to attract
and retain its key employees; and risks inherent in the research,
development, and regulatory approval of new products. More detailed
information on these and additional factors that could affect the
Company’s actual results are described in the “Risk Factors”
section of the Company’s Annual Report on Form 10-K for the year
ended December 31, 2022, and the Company’s Quarterly Report on Form
10-Q for the three months ended September 30, 2023, both of which
have been filed with the Securities and Exchange Commission, and
the Company’s Annual Report on Form 10-K for the year ended
December 31, 2023, which the Company intends to file with the
Securities and Exchange Commission on or before March 31, 2024. The
Company does not assume any obligation to update these
forward-looking statements.
Contact:
Media Contact:
Jacqueline Keller, Vice President of Marketing
(888) 287-9109 ext. 4
info@clearpointneuro.com
Investor Relations:
Danilo D’Alessandro, Chief Financial Officer
(888) 287-9109 ext. 3
ir@clearpointneuro.com
ClearPoint Neuro (NASDAQ:CLPT)
Historical Stock Chart
From Mar 2024 to Apr 2024
ClearPoint Neuro (NASDAQ:CLPT)
Historical Stock Chart
From Apr 2023 to Apr 2024